Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
N/A N=86 Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Early Allograft Dysfunction · Ischemic Reperfusion Injury · Liver Transplantation
Primary: Early Allograft Dysfunction — 6; 18 Participants
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
N/A N=103 Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 4 N=30 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Renal Transplant Rejection · Immunosuppression
Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
N/A N=30 A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
Acute Graft Rejection · Diabetes
Primary: Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection — 2; 2 Participants
Phase 3 N=223 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Chronic Obstructive Pulmonary · Idiopathic Pulmonary Fibrosis · Cystic Fibrosis
Primary: Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First) — 33; 29; 30 participants
N/A N=245 Tissue Oxygenation During Treatment of Infant Congenital Heart Defects
Acute Kidney Injury · Hypoxia-Ischemia, Brain · Mesenteric Ischemia
Primary: Number of Participants With Acute Kidney Injury — 18; 57 Participants
N/A N=50 Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32
Phase 2 N=20 Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
Phase 2 N=16 DCreg in Living Donor Liver Transplantation
Living Donor Liver Transplantation
Primary: Proportion of Safety Events — 1 Participants
Phase 2 N=110 A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
Phase 2 N=30 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Phase 2 N=506 The Effect of Nebulized Albuterol on Donor Oxygenation
Brain Death · Organ Donor · Pulmonary Edema
Primary: Donor Oxygenation — 49; 40 cmH2O — p=0.98
Phase 4 N=30 Spironolactone After Liver Transplant
Transplant, Liver
Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
Phase 2 N=100 Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Liver Transplant · Liver Transplantation
Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants
Phase 4 N=36 Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Number of Subjects With a Perfusion Defect — 5; 6 Participants
Phase 2 N=2 Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Kidney Transplant · Type 1 Diabetes
Primary: The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets. — 0; 2; 2; 1 Participants
N/A N=85 Endothelial Function After Cardiac Surgery
Endothelial Dysfunction
Primary: Reactive Hyperemia Index (RHI) — 1.88; 1.61 ratio — p=0.158
Phase 2 N=26 Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Phase 4 N=341 Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
Renal Function
Primary: Measured Glomerular Filtration Rate — 51.5; 47.8 mL/min/1.73m^2